(Q24245574)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235363%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

0 references

1 reference

title

Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235363%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235363%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

David Rees

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235363%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

J Howard

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235363%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

C Hyde

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235363%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

P Alderson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235363%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

S Brunskill

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235363%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

19 October 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235363%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

8 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235363%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235363%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

CD004450

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235363%20AND%20SRC:MED&resulttype=core&format=json

Long-term Chelation Therapy in Thalassaemia Major: Effect on Liver Iron Concentration, Liver Histology, and Clinical Progress

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation. Nearly two decades of experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Ocular toxicity of high-dose intravenous desferrioxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Effect of different treatment regimes on linear growth and final height in beta-thalassaemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Hepatic lipid peroxidation in vivo in rats with chronic iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Survival and disease complications in thalassemia major.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Rapid desensitisation for desferrioxamine anaphylactoid reaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Results of long-term iron-chelating therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

21 January 2018

The beta-thalassemias

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Prevention of iron loading in transfusion-dependent thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Iron absorption and loading in beta-thalassaemia intermedia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Oral iron chelation therapy for thalassaemia: an uncertain scene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

The toxic effects of desferrioxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Oral deferiprone for iron chelation in people with thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Systematic Reviews in Health Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Urinary zinc excretion and zinc status of patients with beta-thalassemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Prolonged survival in patients with beta-thalassemia major treated with deferoxamine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Chelation therapy in β-thalassemia major. I. Intravenous and subcutaneous deferoxamine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Deferoxamine-induced growth retardation in patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Evaluation of a new method of administration of the iron chelating agent deferoxamine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Oral desferrioxamine in young patients with thalassaemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Rapid desensitisation for desferrioxamine anaphylactic reaction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Survival and causes of death in thalassaemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Early iron reduction programme for thalassaemia patients after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Iron chelators for thalassaemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Combined therapy with deferiprone and desferrioxamine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Safety profile of the oral iron chelator deferiprone: a multicentre study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Reassessment of the Use of Desferrioxamine B in Iron Overload

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Continuous subcutaenous administration of deferoxamine in patients with iron overload

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Survival in medically treated patients with homozygous beta-thalassemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Iron-chelation therapy with oral deferiprone in patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Continuous desferrioxamine infusion by an infusor in thalassaemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Erythropoiesis: Comparison of Cytotoxic Aldehyde Generation in Beta-Thalassemia Patients Chelated with Deferoxamine or Deferiprone (L1) Versus NO Chelation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

The Effect of Ascorbic Acid Deficiency on Desferrioxamine-Induced Urinary Iron Excretion

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Survival and desferrioxamine in thalassaemia major.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Secondary iron overload

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

Pituitary function in thalassemic patients and the effect of chelation therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB2

7 January 2021

10.1002/14651858.CD004450.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235363%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference